Keywords: raloxifene, approval, hots, up, osteoporosis, treatment, market
Raloxifene approval hots up osteoporosis treatment market
Article | 11 October 1999
The US Food and Drug Administration has backed an expanded indicationfor Eli Lilly's selective estrogen receptor modulator, Evista (raloxifene), for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
